Endogenous cartilage cell implants are used for the treatment of extensive cartilage injuries of the knee joint with very good clinical results.

Together with physicians from the Berufsgenossenschaftliche Unfallklinik Tübingen, a leading therapy procedure in Europe was developed to market readiness and licensed and marketed by TETEC AG, which was founded by the NMI in 2000.

Other cell-based drugs, so-called ATMPs for regenerative medicine, such as injectable intervertebral discs and nerve guidance splints, are in the approval or preclinical development phase. Novel biomaterials play a key role in this. Together with Cellendes GmbH, founded in 2009, the NMI has developed intelligent biomaterials that represent a success factor for new regenerative treatment methods.